Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

v3.22.4
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
$ in Thousands
 1 Months Ended 6 Months Ended 12 Months Ended
Oct. 06, 2021
Sep. 30, 2022
Aug. 31, 2022
Jan. 31, 2022
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Agreements                
Long-term royalty and commercial payment receivables         $ 63,683 $ 63,683 $ 69,075 $ 34,575
Contingent consideration under RPAs and CPPAs         75 75 8,075  
Impairment of long-term royalty receivable           0 0  
Affitech                
Agreements                
Reduction in long-term royalty receivable balance due to receipt of payment           526    
Affitech | Commercial Payment Purchase Agreement                
Agreements                
Upfront payment $ 6,000              
Payments eligible to receive (as a percent) 0.50%              
Commercial payment receivable term 10 years              
Maximum additional payments upon achievement of regulatory and sales milestones $ 20,000              
Long-term royalty and commercial payment receivables 14,000              
Maximum payable on regulatory milestone 8,000              
Maximum payable on sales milestone 12,000              
Contingent consideration under RPAs and CPPAs $ 8,000       0 0 $ 8,000  
Milestone payment   $ 3,000   $ 5,000        
Reduction in long-term royalty receivable balance due to receipt of payment     $ 500          
Impairment of long-term royalty receivable           $ 0    
Affitech | Commercial Payment Purchase Agreement | VABYSMO                
Agreements                
Payments eligible to receive (as a percent)   0.50%            
Commercial payment receivable term   10 years            
Cash receipts for achievement of contractual milestones     $ 500   $ 2,400